ACLX · Insider Trading
Arcellx, Inc. Common Stock
Every open-market purchase and sale reported by ACLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-28 | Ali Behbahani | Director | U | −4,631 | — |
| 2026-04-28 | Kavita Patel | Director | D | −76,234 deriv. | — |
| 2026-04-28 | David Charles Lubner | Director | U | −21,659 | — |
| 2026-04-28 | Jill Carroll | Director | U | −1,479,148 | — |
| 2026-04-28 | Olivia C Ware | Director | D | −65,450 deriv. | — |
| 2026-04-28 | Andrew H Galligan | Director | U | −5,000 | — |
| 2026-04-28 | Kristin Myers | Director | D | −18,613 deriv. | — |
| 2026-04-28 | Michelle Gilson | CHIEF FINANCIAL OFFICER | U | −72,048 | — |
| 2026-04-28 | Christopher Heery | CHIEF MEDICAL OFFICER | U | −23,749 | — |
| 2026-04-28 | Rami Elghandour | SEE REMARKS | U | −692,551 | — |
| 2026-04-17 | Michelle Gilson | CHIEF FINANCIAL OFFICER | M | +38,110 | +$330.03K |
| 2026-03-19 | Michelle Gilson | CHIEF FINANCIAL OFFICER | G | −5,000 | — |
| 2026-03-04 | Rami Elghandour | SEE REMARKS | G | −101,164 | — |
| 2026-02-27 | Rami Elghandour | SEE REMARKS | MIXED | +74,632 | −$10.24M |
| 2026-02-25 | Michelle Gilson | CHIEF FINANCIAL OFFICER | MIXED | +9,311 | −$1.28M |
| 2026-02-19 | Michelle Gilson | CHIEF FINANCIAL OFFICER | MIXED | +6,956 | −$572.57K |
| 2026-02-18 | Michelle Gilson | CHIEF FINANCIAL OFFICER | MIXED | +9,205 | −$784.78K |
| 2026-02-13 | Rami Elghandour | SEE REMARKS | G | −198,000 | — |
| 2026-02-13 | Rami Elghandour | SEE REMARKS | G | −218,500 | — |
| 2026-01-20 | David Charles Lubner | Director | MIXED | — | −$412.32K |
| 2026-01-14 | Christopher Heery | CHIEF MEDICAL OFFICER | MIXED | +7,182 | −$403.00K |
| 2026-01-13 | Christopher Heery | CHIEF MEDICAL OFFICER | MIXED | +9,083 | −$487.21K |
| 2026-01-12 | Christopher Heery | CHIEF MEDICAL OFFICER | MIXED | +6,890 | −$393.29K |
| 2026-01-06 | Michelle Gilson | CHIEF FINANCIAL OFFICER | M | +56,366 | — |
| 2026-01-06 | Rami Elghandour | SEE REMARKS | M | +164,548 | — |
| 2026-01-06 | Christopher Heery | CHIEF MEDICAL OFFICER | M | +42,605 | — |
| 2025-11-17 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | −340 | −$30.60K |
| 2025-10-15 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sell | −5,364 | −$488.32K |
| 2025-10-06 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sell | −5,946 | −$511.60K |
| 2025-09-30 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | −21,034 | −$1.71M |
| 2025-09-29 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | −73 | −$5.85K |
| 2025-09-26 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | −12,396 | −$993.16K |
| 2025-09-19 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | −3,643 | −$291.47K |
| 2025-08-29 | Rami Elghandour | SEE REMARKS | F | −546,938 | −$38.42M |
| 2025-08-14 | Ali Behbahani | Director | J | +4,207 | — |
| 2025-06-11 | Kavita Patel | Director | MIXED | — | −$91.05K |
| 2025-05-30 | David Charles Lubner | Director | A | +9,174 deriv. | — |
| 2025-05-30 | Kristin Myers | Director | A | +1,784 deriv. | — |
| 2025-05-30 | Kavita Patel | Director | A | +9,174 deriv. | — |
| 2025-05-30 | Jill Carroll | Director | A | +9,174 deriv. | — |
| 2025-05-30 | Andrew H Galligan | Director | A | +1,784 deriv. | — |
| 2025-05-30 | Olivia C Ware | Director | A | +9,174 deriv. | — |
| 2025-05-30 | Ali Behbahani | Director | A | +9,174 deriv. | — |
| 2025-05-28 | Michelle Gilson | CHIEF FINANCIAL OFFICER | MIXED | +10,194 | −$784.78K |
| 2025-05-20 | Kavita Patel | Director | MIXED | — | −$77.66K |
| 2025-04-29 | Kavita Patel | Director | MIXED | — | −$86.31K |
| 2025-04-08 | Kavita Patel | Director | MIXED | — | −$76.26K |
| 2025-03-20 | Andrew H Galligan | Director | A | +16,829 deriv. | — |
| 2025-03-20 | Kristin Myers | Director | A | +16,829 deriv. | — |
| 2025-03-18 | Kavita Patel | Director | MIXED | — | −$97.47K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Olivia C Ware | Director | 9,402 | $1.08M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACLX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.